Repurposing of cefpodoxime proxetil as potent neuroprotective agent through computational prediction and in vitro validation
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Biomolecular Structure and Dynamics"
DOI: 10.1080/07391102.2020.1772884
Abstract: Abstract In recent reports, NR2B-NMDA receptor antagonists showed more research value because of its strong targeting ability and less side effects potential. In 2016, EVT-101 was reported to bind in an almost entirely new binding… read more here.
Keywords: repurposing cefpodoxime; neuroprotective agent; proxetil potent; cefpodoxime proxetil ... See more keywords
Cefpodoxime proxetil as a therapeutic option in switching therapy for infective endocarditis in children: case reports and literature review
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Chemotherapy"
DOI: 10.1080/1120009x.2019.1603797
Abstract: Infective endocarditis (IE) is uncommon in children, affecting predominantly subjects with congenital heart disease (CHD) and patients with indwelling central lines. The principles of antibiotic treatment in paediatric population are similar to those in adults.… read more here.
Keywords: switching therapy; therapy; infective endocarditis; cefpodoxime proxetil ... See more keywords
Bioequivalence of two tablet formulations of cefpodoxime proxetil in beagle dogs
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Veterinary Science"
DOI: 10.3389/fvets.2022.1048823
Abstract: The pharmacokinetic profiles and bioequivalence of two cefpodoxime proxetil tablets were investigated in Beagle dogs. A single-dose, four-way complete replication and crossover design was used in the present study. A total of 28 healthy Beagle… read more here.
Keywords: cefpodoxime proxetil; bioequivalence two; bioequivalence; beagle dogs ... See more keywords